Patients who received Remicade for inflammatory bowel disease had weakened anti-COVID-19 antibody responses following a single vaccination dose, according to research published in Gut.

In a prospective, observational cohort study, researchers compared antibody responses and seroconversion rates in Remicade-treated (infliximab, Janssen) patients (n = 856) vs. Entyvio-treated (vedolizumab, Takeda) patients (n = 428) 3-weeks to 10-weeks after receiving a single dose of a SARS-CoV-2 vaccine.

According to study results, patients treated with infliximab had lower anti-SARS-CoV-2 antibody

Full Article: